NDC 68788-8563-01 - Gabapentin
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 68788-8563
- Requested NDC
- 68788-8563-01
- Package NDCs from labels
- 68788-8563-3, 68788-8563-6, 68788-8563-9, 68788-8563-1, 68788-8563-8, 68788-8563-01
- Manufacturer
- Preferred Pharmaceuticals Inc.
- Effective date
- 2026-04-29
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Gabapentin - Preferred Pharmaceuticals Inc. | Preferred Pharmaceuticals Inc. | 2026-04-29 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 68788-8563-1 | Gabapentin | 100 in 1 BOTTLE, PLASTIC | CAPSULE | 100 | 3 | |
| 68788-8563-3 | Gabapentin | 30 in 1 BOTTLE, PLASTIC | CAPSULE | 30 | 3 | |
| 68788-8563-6 | Gabapentin | 60 in 1 BOTTLE, PLASTIC | CAPSULE | 60 | 3 | |
| 68788-8563-8 | Gabapentin | 120 in 1 BOTTLE, PLASTIC | CAPSULE | 120 | 3 | |
| 68788-8563-9 | Gabapentin | 90 in 1 BOTTLE, PLASTIC | CAPSULE | 90 | 3 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 68788-8563 | GABAPENTIN CAPSULE [PREFERRED PHARMACEUTICALS INC.] | 1 | Current NDC, 5 package rows | 20240206_2625c0ef-5295-41de-9e81-88001a6cbecc.zip |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 68788-8563-1 | EA - Each | 68788-8563 | 2d1f267e-3ef0-40a5-909c-b3d4c50e2862 | 1 | 2024-05-16 |
| 68788-8563-3 | EA - Each | 68788-8563 | b1437b10-b861-44f9-978a-5bc2b13193f3 | 1 | 2024-05-16 |
| 68788-8563-6 | EA - Each | 68788-8563 | 202d078f-b330-4a18-a7dd-a3b5820525eb | 1 | 2024-05-16 |
| 68788-8563-8 | EA - Each | 68788-8563 | 90fccd51-866b-40bb-bb13-63eabd8c8072 | 1 | 2024-05-16 |
| 68788-8563-9 | EA - Each | 68788-8563 | 47068409-e4a7-4d55-bb57-f3418778c8ca | 1 | 2024-05-16 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| GABAPENTIN | GABAPENTIN | Preferred Pharmaceuticals Inc. | 38119f2e-33b3-4c3c-99b7-9335d8d280d4 | 2026-05-01 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | St. Mary's Medical Park Pharmacy | b8b7e045-a7fe-8539-e053-2a95a90a40f8 | 2026-05-01 | Warnings, Adverse reactions | ANDA204989 310430 6CW7F3G59X |
| Gabapentin | GABAPENTIN | St Mary's Medical Park Pharmacy | de990f96-96bc-406d-e053-2995a90abebb | 2026-05-01 | Warnings, Adverse reactions | 310431 6CW7F3G59X |
| Blue Lizard Sport SPF 50 Sunscreen | OCTISALATE AND TITANIUM DIOXIDE AND ZINC OXIDE | Crown Laboratories | 4955fa1c-789d-4f42-af75-70223310644a | 2026-05-01 | Warnings | 15FIX9V2JP |
| Blue Lizard Kids SPF 50 Sunscreen | OCTISALATE AND TITANIUM DIOXIDE AND ZINC OXIDE | Crown Laboratories | ba4ae906-48c0-8384-e053-2995a90afb91 | 2026-05-01 | Warnings | 15FIX9V2JP |
| Gabapentin | GABAPENTIN | Bryant Ranch Prepack | 4cb26d6e-7963-4fe5-903e-ab5180545066 | 2026-05-01 | Warnings, Adverse reactions | 6CW7F3G59X |
| Dior Backstage Glow-Up Skin Tint Tinted Moisturizer SPF 20 2CR Cool Rosy | OCTISALATE, TITANIUM DIOXIDE | Parfums Christian Dior | 6831832a-e52e-43ea-899f-f5d44bea5a94 | 2026-04-30 | Warnings | 15FIX9V2JP |
| Tru Skin Rituals SPF 25 | TITANIUM DIOXIDE, ZINC OXIDE | Spa de Soleil | f725cd5c-999e-2393-e053-6394a90a09dc | 2026-04-30 | Warnings | 15FIX9V2JP |
| Gabapentin | GABAPENTIN | Preferred Pharmaceuticals Inc. | 100ff86c-56a8-4770-9db3-b9bc6b1bd2f7 | 2026-04-30 | Warnings, Adverse reactions | ANDA204989 310432 6CW7F3G59X |
| TiZO2 | TITANIUM DIOXIDE, ZINC OXIDE | Fallien Cosmeceuticals Ltd. | 509cad98-0321-2a0a-e063-6294a90a6ea9 | 2026-04-29 | Warnings | 15FIX9V2JP |
| TiZO2 | TITANIUM DIOXIDE, ZINC OXIDE | Fallien Cosmeceuticals Ltd. | 509d7206-0cc1-c997-e063-6294a90a89e0 | 2026-04-29 | Warnings | 15FIX9V2JP |
| Gabapentin | GABAPENTIN | PD-Rx Pharmaceuticals, Inc. | d22ed424-f365-44ca-8ef9-a08255a90ae8 | 2026-04-29 | Warnings, Adverse reactions | 6CW7F3G59X |
| JMSOLUTION SKIN BOOST NIACINAMIDE SUNSCREEN | HOMOSALATE, OCTISALATE, OCTOCRYLENE, TITANIUM DIOXIDE | GPNY CORP | 211dea04-faad-8ffc-e063-6294a90a8d68 | 2026-04-29 | Warnings | 15FIX9V2JP |
| Gabapentin | GABAPENTIN | Preferred Pharmaceuticals Inc. | e3429322-c442-4146-bb68-bcc3a8d01552 | 2026-04-29 | Warnings, Adverse reactions | ANDA204989 310430 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Preferred Pharmaceuticals Inc. | 2625c0ef-5295-41de-9e81-88001a6cbecc | 2026-04-29 | Warnings, Adverse reactions | ANDA204989 68788-8563-6 68788-8563-9 68788-8563-8 68788-8563-3 68788-8563-1 68788-8563 68788856301 310430 561b2673-98f8-484f-88a7-0bc7e46314eb 2625c0ef-5295-41de-9e81-88001a6cbecc 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Preferred Pharmaceuticals Inc. | 6ecf5114-2ddc-4025-a36d-1884702dc22a | 2026-04-29 | Warnings, Adverse reactions | 310430 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Preferred Pharmaceuticals Inc. | f396ec70-826d-45c6-a27c-343c2fac878c | 2026-04-29 | Warnings, Adverse reactions | 310430 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Preferred Pharmaceuticals, Inc. | 41dcc917-68d1-49f0-8223-44c21ca259ef | 2026-04-29 | Warnings, Adverse reactions | ANDA204989 310431 6CW7F3G59X |
| Anything SPF | OCTINOXATE, OCTISALATE, ZINC OXIDE, AVOBENZONE, HOMOSALATE, TITANIUM DIOXIDE | Anything SPF LLC | 508b8dcb-6600-6dad-e063-6294a90a565a | 2026-04-28 | Warnings | 15FIX9V2JP |
| Gabapentin | GABAPENTIN | Coupler LLC | 5073abda-321f-29d1-e063-6394a90a59ac | 2026-04-27 | Warnings, Adverse reactions | ANDA204989 310430 6CW7F3G59X |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.